Please use this identifier to cite or link to this item:
Title: Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
Austin Authors: Bhurani, Mansi;Admojo, Lorenz;Van Der Weyden, Carrie;Twigger, Robert;Bazargan, Ali;Quach, Hang;Zimet, Allan;Coyle, Luke;Lindsay, Julian;Radeski, Dejan;Hawkes, Eliza A ;Kennedy, Glen;Irving, Ian;Gutta, Naadir;Trotman, Judith;Yeung, James;Dunlop, Lindsay;Hua, Minh;Giri, Pratyush;Yuen, Sam;Panicker, Shyam;Moreton, Susan;Khoo, Liane;Scott, Ashleigh;Kipp, David;McQuillan, Andrew;McCormack, Chris;Dickinson, Michael;Prince, Henry Miles
Affiliation: Royal Adelaide Hospital, Adelaide, SA, Australia
Southern Highland Private Hospital, Liverpool, NSW, Australia
Royal Prince Alfred Hospital, Sydney, NSW, Australia
Concord Hospital, Sydney, NSW, Australia
Icon Cancer Care, Brisbane, QLD, Australia
Mater Cancer Care Centre, Brisbane, QLD, Australia
Olivia Newton-John Cancer Research Institute
Hollywood Medical Centre, Nedlands, WA, Australia
Barwon Health Cancer Services, Geelong, VIC, Australia
Hills Specialist Group, Bella Vista, NSW, Australia
Calvary Mater, Newcastle, NSW, Australia
St Vincent's Health, Melbourne, VIC, Australia
Royal Brisbane and Women's Hospital, Herston, QLD, Australia
Sir Peter MacCallum Department of Surgical Oncology, Parkville, VIC, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
Sir Charles Gairdner Hospital, Nedlands, WA, Australia
Royal North Shore Hospital, Sydney, NSW, Australia
Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, VIC, Australia
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Dubbo Base Hospital, Dubbo, NSW, Australia
Epworth Healthcare, Melbourne, VIC, Australia
Issue Date: Feb-2021
Date: 2020-10-07
Publication information: Leukemia & Lymphoma 2021; 62(2): 330-336
Abstract: We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan-Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (nā€‰=ā€‰11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study - the second largest real-world cohort reported to date - underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile.
DOI: 10.1080/10428194.2020.1827241
ORCID: 0000-0001-6566-6215
Journal: Leukemia & Lymphoma
PubMed URL: 33026266
Type: Journal Article
Subjects: Pralatrexate
T-cell lymphoma
cutaneous T-cell lymphoma
peripheral T-cell lymphoma
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 18, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.